IGM Biosciences stock (US4495851085): Cash and stock merger completed

IGM Biosciences, Inc. (IGMS) executed a cash and stock merger, with shareholders receiving $1.2470 cash plus 1.0000 share of IGMS^ per share, per recent corporate action update.

IGM Biosciences, Inc., a clinical-stage biotechnology company, recently completed a cash and stock merger. Shareholders received $1.2470 in cash and 1.0000 share of IGMS^ for each share of IGMS held, according to the Robinhood corporate actions tracker as of May 2026. This restructuring impacts Nasdaq-listed IGMS shares and is relevant for US retail investors tracking biotech developments.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: IGM Biosciences, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: Oncology, immunology
• Key revenue drivers: Clinical-stage drug candidates
• Home exchange/listing venue: Nasdaq (IGMS)
• Trading currency: USD

IGM Biosciences Inc: core business model

IGM Biosciences Inc develops IgM antibodies for cancer and autoimmune diseases using its IgM drug discovery platform, which enables multispecific antibodies with enhanced immune cell engagement. The company, based in Mountain View, California, focuses on clinical programs like IGM-8444, currently in a phase 1a/1b trial for patients, sponsored by IGM Biosciences as noted on clinical trial registry as of 2026. This platform differentiates IGM from standard IgG therapies.

Founded in 2010, IGM has advanced several candidates into clinical testing, targeting solid tumors and autoimmune conditions. The recent merger reflects strategic adjustments amid biotech sector challenges, providing liquidity and continuity for shareholders.

Main revenue and product drivers for IGM Biosciences Inc

IGM's pipeline leads with IGM-8444, an IgM antibody in an open-label, multicenter phase 1a/1b study coordinated by Investigator Antoine Italiano at Institut Bergonié. Revenue potential hinges on trial outcomes and partnerships, typical for clinical-stage biotechs without approved products. The company reports no commercial revenue as of its latest filings.

Key drivers include progress in oncology trials and potential licensing deals. US investors follow IGM for exposure to innovative antibody tech amid rising demand for targeted therapies.

Conclusion

The cash and stock merger marks a pivotal corporate action for IGM Biosciences Inc, distributing value to shareholders while the company advances its IgM platform in clinical trials. US investors monitor biotech restructurings for opportunities in oncology innovation. Developments in IGM-8444 and pipeline updates remain key focus areas.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.